IBT
ADMS

International Biotechnology Trust’s Adamas Pharmaceuticals ADMS Stock Holding History

International Biotechnology Trust’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-370,000
Closed -$5.67M – 56
2018
Q3 		$5.67M Hold
370,000
– – 2.7% 14
2018
Q2 		$9.55M Hold
370,000
– – 3.67% 10
2018
Q1 		$8.83M Buy
370,000
+55,000
+17% +$1.73M 3.45% 10
2017
Q4 		$10.7M Sell
315,000
-75,000
-19% -$2.09M 3.76% 7
2017
Q3 		$8.25M Buy
390,000
+204,766
+111% +$3.75M 3.21% 9
2017
Q2 		$3.24M Hold
185,234
– – 1.23% 29
2017
Q1 		$3.24M Hold
185,234
– – 1.24% 23
2016
Q4 		$3.13M Buy
+185,234
New +$2.86M 1.41% 18

Other funds holding ADMS

Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

International Biotechnology Trust's ADMS Position: Q4 2018 in Review

International Biotechnology Trust sold out of Adamas Pharmaceuticals (ADMS) in Q4 2018, closing a stake of 370,000 shares — an estimated $5.67M sold.

International Biotechnology Trust first reported a position in ADMS in Q4 2016 and held it in 8 quarters. The position peaked at $10.7M in Q4 2017. 98 funds tracked by Wall St. Rank hold ADMS as of Q4 2018.

  • International Biotechnology Trust reported no remaining Adamas Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • International Biotechnology Trust sold 370,000 Adamas Pharmaceuticals shares in Q4 2018, an estimated $5.67M.
  • International Biotechnology Trust first reported a position in Adamas Pharmaceuticals in Q4 2016 and held it in 8 quarters.
  • International Biotechnology Trust's Adamas Pharmaceuticals position peaked at $10.7M in Q4 2017.
  • 98 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2018.

Based on International Biotechnology Trust's 13F filing for Q4 2018, filed 14 Feb 2019.